Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Ratutrelvir (83-0060) non-randomised
Ratutrelvir non-randomised · 1 trial · 1 indication
Adverse events incidence will be described using descriptive statistics methods
Adverse events severity will be assessed by current version of CTCAE
| Arm | Type | Description |
|---|---|---|
| Ratutrelvir (83-0060) non-randomised | EXPERIMENTAL | - |
| Paxlovid | ACTIVE_COMPARATOR | Standard of care |
| Ratutrelvir (83-0060) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Ratutrelvir (83-0060) non-randomised | DRUG | 83-0060, a covalent inhibitor of the SARS-CoV-2 main protease (Mpro; 3CL) |
| Paxlovid | DRUG | Paxlovid (Nirmatrelvir+ Ritonavir , boosted 3CL-protease inhibitor) |
| Ratutrelvir (83-0060) | DRUG | 83-0060, a covalent inhibitor of the SARS-CoV-2 main protease (Mpro; 3CL) |
Inclusion Criteria: 1. Confirmed SARS-CoV-2 infection for 120 h prior to randomization. 2. Initial onset of signs/symptoms attributable to COVID-19 within 5 days prior to randomization. 3. At least one of the symptoms attributable to COVID-19 present within 24 hours prior to the Day 1 with the seve...
Ratutrelvir is an investigational small molecule being developed for the treatment of COVID-19. It is currently in Phase 2 clinical development for patients with mild to moderate COVID-19. The drug is being studied to determine a safe and effective dose in this patient population.
Ratutrelvir is being developed by Traws Pharma, Inc., a biopharmaceutical company. The company is listed on the stock exchange under the ticker symbol TRAW. Traws Pharma is conducting clinical trials to evaluate the safety and efficacy of Ratutrelvir for the treatment of COVID-19.
Ratutrelvir is currently in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 2 trial is recruiting patients with mild to moderate COVID-19 to determine a safe and effective dose of the drug.
Ratutrelvir is being studied in a Phase 2 clinical trial registered as NCT07157007. This trial is titled 'Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19'. The study is currently recruiting participants and aims to enroll 90 patients.
Yes, Ratutrelvir is also known as Ratutrelvir (83-0060) non-randomised. These names refer to the same investigational drug being developed by Traws Pharma, Inc. for the treatment of COVID-19. The drug is currently in Phase 2 clinical trials.